Atara Biotherapeutics, Inc. (ATRA) Stock Analysis
A live, multi-source view of Atara Biotherapeutics, Inc. (ATRA): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Sector: Healthcare · Industry: Biotechnology · United States · 10 employees · atarabio.com
Key statistics · as of 2026-09-09
As of 2026-09-09, Atara Biotherapeutics, Inc. (ATRA) had a market capitalization of $102.7M (forward 6.6) and a beta of 0.11; the shares traded in a 52-week range of $3.92 – $19.14 (-17.1% over the year).
- Market cap
- $102.7M
- Enterprise value
- $102.7M
- Forward P/E
- 6.6
- EPS (trailing)
- $-1.53
- EPS (forward)
- $1.54
- Payout ratio
- 0.0%
- 52-week range
- $3.92 – $19.14
- 52-week change
- -17.1%
- Beta
- 0.11
- Average volume
- 66,047
- Shares outstanding
- 10.0M
- Short % of float
- 6.49%
- Profit margin
- -269.4%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Atara Biotherapeutics, Inc. (ATRA) last closed at $9.91 (the last completed close before that scan).
Technicals at the scan: RSI 58 (neutral territory), price +6.8% versus its 20-day average, 20-day versus 50-day average spread +2.2%, MACD histogram 0.09.
Sentiment inputs: StockTwits 30% bullish; analyst consensus score 69/100.
Next scheduled company event: in 63 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of ATRA; corporate insiders filed 1 buy and 0 sells (1 filer, latest disclosure 2026-09-04). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Brian N. Cherry (1B/0S). Who is trading what
RapidTradeView pick record
ATRA has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Atara Biotherapeutics, Inc. (ATRA) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell ATRA.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.